Insider Selling: Phreesia (NYSE:PHR) Director Sells 2,546 Shares

Phreesia, Inc. (NYSE:PHR) Director Lisa Egbuonu-Davis sold 2,546 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $9.53, for a total value of $24,263.38. Following the transaction, the director directly owned 38,316 shares of the company’s stock, valued at $365,151.48. This represents a 6.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Phreesia Stock Up 9.1%

Shares of PHR stock traded up $0.83 during mid-day trading on Friday, reaching $9.96. 2,996,859 shares of the company’s stock traded hands, compared to its average volume of 1,777,366. The company’s 50-day moving average price is $9.33 and its 200-day moving average price is $12.01. The company has a market cap of $615.96 million, a P/E ratio of 66.43 and a beta of 0.91. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.41. Phreesia, Inc. has a 12 month low of $7.77 and a 12 month high of $32.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, May 27th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. Phreesia had a net margin of 1.85% and a return on equity of 5.13%. The company had revenue of $130.94 million during the quarter, compared to analyst estimates of $130.08 million. During the same period last year, the business earned ($0.07) EPS. Phreesia’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, equities analysts expect that Phreesia, Inc. will post 0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PHR. Citigroup reaffirmed a “market perform” rating on shares of Phreesia in a research report on Friday, May 29th. Barclays restated an “equal weight” rating and set a $10.00 price objective (down from $24.00) on shares of Phreesia in a research note on Thursday, May 14th. Truist Financial lifted their target price on shares of Phreesia from $11.00 to $12.00 and gave the stock a “hold” rating in a report on Thursday, May 28th. Stephens decreased their price target on Phreesia from $32.00 to $20.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Finally, BMO Capital Markets dropped their price target on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Phreesia has an average rating of “Hold” and an average target price of $16.65.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Phreesia shareholders backed the company’s leadership and governance at the annual meeting, suggesting continued investor support for management. Article Title
• Neutral Sentiment: Brokerage coverage remained mixed-to-stable, with Phreesia reportedly carrying a consensus “Hold” rating, which does not signal a major new catalyst. Article Title
• Negative Sentiment: Several law firms issued class-action and investigation notices regarding alleged securities law violations, increasing legal overhang and uncertainty for PHR shares. Article Title
• Negative Sentiment: Deadline reminders for the July 13 lead-plaintiff cutoff keep the securities-fraud case in focus, which can pressure the stock as investors digest litigation risk. Article Title

Hedge Funds Weigh In On Phreesia

Institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. grew its holdings in Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after purchasing an additional 375 shares during the period. Alliancebernstein L.P. raised its stake in shares of Phreesia by 1.3% in the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock worth $1,475,000 after buying an additional 812 shares during the period. Van ECK Associates Corp raised its stake in shares of Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after buying an additional 1,102 shares during the period. Deutsche Bank AG lifted its position in shares of Phreesia by 2.4% during the 4th quarter. Deutsche Bank AG now owns 66,288 shares of the company’s stock valued at $1,122,000 after buying an additional 1,540 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after buying an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.